Identification of pathways modulating Vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen

Abstract excerpt

<h4>ABSTRACT</h4> Vemurafenib is a BRAF kinase inhibitor (BRAFi) that is used to treat melanoma patients harbouring the constitutively active BRAF-V600E mutation. However, after a few months of treatment patients often develop resistance to vemurafenib leading to disease progression. Sequence analysis of drug-resistant tumour cells and functional genomic screens have identified several genes that regulate vemuraf...

Topics

Open a Topic to create a Post that cites this publication.

• Cell Line, Tumor
• Clustered Regularly Interspaced Short Palindromic Repeats
• CRISPR-Cas Systems
• Drug Resistance, Neoplasm
• Melanoma
• Melanoma and MAPK Pathways
• Mutation
• Vemurafenib

Identifiers and source

Literature Corpus work

65db2d65-7df3-5bd4-bc00-cc18db762e06

DOI

10.1101/2020.07.11.198911